ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study

Statement from Bruce E. Johnson, MD, FASCO, President of the American Society of Clinical Oncology (ASCO)
For immediate release
February 20, 2018
Contact
Julianne Lee
571-483-1381
julianne.lee@asco.org

“This research further highlights the fact that combustible tobacco products cause many types of cancer. It also emphasizes why the Food and Drug Administration should use its authority to regulate cigars and pipe and hookah tobacco.

“ASCO is committed to reducing the burden of smoking-related cancer mortality and protecting public health. The Society strongly supports congressional efforts to maintain the FDA's regulatory authority over cigarettes and other tobacco products and promotes the increase of smoking cessation.

“We commend the study authors for their research that reaffirms the elevated risks of all combustible tobacco products.”

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO
works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.